AstraZeneca raises guidance on stellar cancer drugs growth AZ reports strong financial results for 2025, and provides a first peek at the data for its oral GLP-1 contender elecoglipron

#AstraZeneca #PascalSoriot #cancertherapies #oncologyproducts #commercialperformance #blockbusterbrands #cancer #weightloss #genetherapies #antiHER2therapy #prostatecancer #breastcancer #asthma #respiratorysyncytialvirus #RSV #RSVprophylactic #lupus #phase2trials #phase3trials
zurl.co/yLEDf